This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weckbecker, G. Articles by Bruns, C. Search for Related Content PubMed PubMed Citation Articles by Weckbecker, G. Articles by Bruns, C.

Somatostatin Analogue Octreotide Enhances the Antineoplastic Effects of Tamoxifen and Ovariectomy on 7,12-Dimethylbenz(a)anthracene-induced Rat Mammary Carcinomas¹

Preclinical Research, Sandoz Pharma, 386/627, CH-4002 Basel, Switzerland [G. W., L. T., B. S., C. B.], and Lady Davis Research Institute of the Jewish General Hospital and McGill University, Montreal, Quebec, Canada H3T 1E2 [M. P.]

The efficacy of tamoxifen and ovariectomy in the management of breast cancer is limited by the resistance of many neoplasms to these endocrine therapies and by the fact that initially responding tumors often escape from control during long-term treatment. We evaluated the effect of coadministration of the somatostatin analogue octreotide, which has single agent activity in several in vivo and in vitro breast cancer models, on the antineoplastic actions of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced mammary tumors. Rats received tamoxifen (0.5 mg/kg twice weekly s.c.), octreotide (10 µg/kg/h for 6 weeks by osmotic minipump), or the combination 7 weeks following 7,12-dimethylbenz(a)anthracene administration. The number of tumors per animal and the sum of the volumes of palpable tumors per animal were significantly less in the combination treatment than in the others. In ovariectomized rats the marked regression of established tumors in the initial 4 weeks after ovariectomy was frequently followed by tumor regrowth. However, continuous infusion of octreotide (50 µg/kg/h for 6 weeks postovariectomy) significantly (P < 0.01) suppressed this regrowth. Our data suggest that octreotide enhances the antitumor effects of tamoxifen or ovariectomy in the 7,12-dimethylbenz(a)anthracene mammary cancer model.

¹ Supported in part by a National Cancer Institute of Canada Grant to M. P.

² To whom requests for reprints should be addressed.

³ These authors contributed equally to this study.

Received 10/ 7/94. Accepted 11/ 3/94.

This article has been cited by other articles:

				G. Thordarson, A. V. Lee, M. McCarty, K. Van Horn, O. Chu, Y.-C. Chou, J. Yang, R. C. Guzman, S. Nandi, and F. Talamantes Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats Carcinogenesis, December 1, 2001; 22(12): 2039 - 2047. [Abstract] [Full Text] [PDF]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				J. P. van Netten, S. A. Cann, N. G. van der Westhuizen, H. Paran, D. Paran, F. Puglisi, S. Scalone, V. DiLauro, and J. Folkman Angiogenesis and Tumor Growth N. Engl. J. Med., April 4, 1996; 334(14): 920 - 921. [Full Text]